DK0642352T3 - Afkortet vævsfaktor og FVIIa- eller FVII-aktivator til blodkoagulation - Google Patents

Afkortet vævsfaktor og FVIIa- eller FVII-aktivator til blodkoagulation

Info

Publication number
DK0642352T3
DK0642352T3 DK93913844T DK93913844T DK0642352T3 DK 0642352 T3 DK0642352 T3 DK 0642352T3 DK 93913844 T DK93913844 T DK 93913844T DK 93913844 T DK93913844 T DK 93913844T DK 0642352 T3 DK0642352 T3 DK 0642352T3
Authority
DK
Denmark
Prior art keywords
fviia
ttf
activator
tissue factor
truncated tissue
Prior art date
Application number
DK93913844T
Other languages
English (en)
Inventor
H Morrissey James
C Comp Philip
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/882,202 external-priority patent/US5374617A/en
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of DK0642352T3 publication Critical patent/DK0642352T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93913844T 1992-05-13 1993-05-12 Afkortet vævsfaktor og FVIIa- eller FVII-aktivator til blodkoagulation DK0642352T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/882,202 US5374617A (en) 1992-05-13 1992-05-13 Treatment of bleeding with modified tissue factor in combination with FVIIa
US08/021,615 US5504064A (en) 1991-04-10 1993-02-19 Treatment of bleeding with modified tissue factor in combination with an activator of FVII
PCT/US1993/004493 WO1993023074A1 (en) 1992-05-13 1993-05-12 TRUNCATED TISSUE FACTOR AND FVIIa OR FVII ACTIVATOR FOR BLOOD COAGULATION

Publications (1)

Publication Number Publication Date
DK0642352T3 true DK0642352T3 (da) 1999-09-13

Family

ID=26694897

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93913844T DK0642352T3 (da) 1992-05-13 1993-05-12 Afkortet vævsfaktor og FVIIa- eller FVII-aktivator til blodkoagulation

Country Status (10)

Country Link
US (1) US5504064A (da)
EP (1) EP0642352B1 (da)
JP (1) JP3663550B2 (da)
AT (1) ATE175876T1 (da)
AU (1) AU676168B2 (da)
CA (1) CA2134750C (da)
DE (1) DE69323195T2 (da)
DK (1) DK0642352T3 (da)
ES (1) ES2127286T3 (da)
WO (1) WO1993023074A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6017891A (en) * 1994-05-06 2000-01-25 Baxter Aktiengesellschaft Stable preparation for the treatment of blood coagulation disorders
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE4416180C2 (de) * 1994-05-06 1997-08-14 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats
EP0771216B9 (en) * 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
JP2000500348A (ja) * 1995-11-22 2000-01-18 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 血液凝固第▲ｖｉｉｉ▼因子および第▲ｉｘ▼因子のアッセイ
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
ATE244579T1 (de) * 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
DE69832628T2 (de) * 1997-04-23 2006-09-07 Instrumentation Laboratory S.P.A. Rekombinant-kaninchengewebefaktor basiertes prothrombinzeitreagenz
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CA2349501A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
RU2159125C1 (ru) * 1999-06-23 2000-11-20 Шахназаров Зурико Шотович Способ лечения гастродуоденальных язв
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6410733B1 (en) 2000-09-11 2002-06-25 Genentech, Inc. Amidine inhibitors of serine proteases
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US20030211075A1 (en) * 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
WO2003035688A2 (en) * 2001-10-26 2003-05-01 Novartis Pharma Gmbh Targeted thrombosis by tissue factor polypeptides
US7700733B2 (en) * 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
EP1549677B1 (en) * 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
DK2085470T3 (da) * 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
EP2004214B1 (en) 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Local treatment with factor vii
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
WO2009097429A1 (en) * 2008-01-29 2009-08-06 Leon Wortham A fast acting primary hemostatic agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456591A (en) * 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
EP0225160B1 (en) * 1985-11-26 1991-08-21 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
DE3728491A1 (de) * 1987-08-26 1989-03-09 Heumann Pharma Gmbh & Co Dihydropyridazinon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Also Published As

Publication number Publication date
AU4372993A (en) 1993-12-13
JPH07508029A (ja) 1995-09-07
US5504064A (en) 1996-04-02
DE69323195T2 (de) 1999-10-14
EP0642352B1 (en) 1999-01-20
EP0642352A1 (en) 1995-03-15
CA2134750A1 (en) 1993-11-25
ATE175876T1 (de) 1999-02-15
AU676168B2 (en) 1997-03-06
ES2127286T3 (es) 1999-04-16
WO1993023074A1 (en) 1993-11-25
CA2134750C (en) 2008-01-15
JP3663550B2 (ja) 2005-06-22
DE69323195D1 (de) 1999-03-04

Similar Documents

Publication Publication Date Title
ATE175876T1 (de) Verkürzter gewebsfaktor und fviia oder fvii zur aktivierung der blutgerinnung
Esmon The protein C pathway
Mariani et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies
NZ283499A (en) Haemophilia medicament; comprises coagulation factor viii or factor ix
HUT71572A (en) Coagulation inhibiting modified factors vii and pharmaceutical preparations containing them
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
ATE244579T1 (de) Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
ATE233099T1 (de) Eine formulierung des gerinnungsfaktors viii
HU9503312D0 (en) Modified factor vii
ES2063365T3 (es) Composiciones anticoagulantes basadas en el factor xa.
Hedner et al. Management of hemophilia patients with inhibitors
Aledort Recombinant factor VIIa is a pan-hemostatic agent?
Lewandowski et al. Protein C concentrate in the treatment of warfarin-induced skin necrosis in the protein C deficiency
Lucas et al. Epsilon aminocaproic acid in hemophiliacs undergoing dental extractions: a concise review
Pindur et al. The overdosed patient and bleedings with oral anticoagulation
KR960013383A (ko) 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
Ghirardini et al. Clinical evaluation of subcutaneously administered DDAVP
US7429566B2 (en) Method for treating Hemophilia B
Łaguna et al. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors
Cordova et al. Low doses of calcium-heparin in liver cirrhosis
Zech et al. Maintenance of hemostasis during exodontia in two hemophiliacs with factor VIII inhibitors
Mohler et al. EFFECT OF RECOMBINANT TISSUE TYPE PLASMINOGEN ACTIVATOR (rt-Pa) ON THE PREVENTION OF INTRAABDOMINAL ADHESION FORMATION
Lund-Hansen et al. Comparison of enzymatic properties of human plasma FVIIa and human recombinant FVIIa
Van Creveld et al. Dental extractions and the use of Christmas factor concentrate in cases of haemophilia B
Green et al. Warfarin-induced factor VII deficiency and the bleeding time